Failure of dabigatran and rivaroxaban to prevent thromboembolism in antiphospholipid syndrome: A case series of three patients

Thrombosis and Haemostasis

Volumn 112, Issue 5, 2014, Pages 947-950

  Schaefer, Jordan K ^a   McBane, Robert D ^a   Black, David F ^a   Williams, Lindsy N ^a   Moder, Kevin G ^a   Wysokinski, Waldemar E ^a  

^a MAYO CLINIC   (United States)

Author keywords

Antiphospholipid syndrome; Direct oral anticoagulants; Thromboembolic complications; Warfarin

Indexed keywords

CARDIOLIPIN ANTIBODY; CREATININE; DABIGATRAN; ENOXAPARIN; HEPARIN; IMMUNOGLOBULIN G; RIVAROXABAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE; MORPHOLINE DERIVATIVE; THIOPHENE DERIVATIVE; WARFARIN;

ADULT; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BRAIN EMBOLISM; CASE REPORT; CEREBRAL SINUS THROMBOSIS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL (TOPIC); COMPUTED TOMOGRAPHIC ANGIOGRAPHY; CREATININE CLEARANCE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; HUMAN; ISCHEMIC ARTERIAL STROKE; MALE; PROTHROMBIN TIME; THROMBOCYTOPENIA; THROMBOEMBOLISM; THROMBOTIC ENDOCARDITIS; VEIN THROMBOSIS; ANALOGS AND DERIVATIVES; BLOOD; CEREBRAL INFARCTION; COMPLICATION; INTERNATIONAL NORMALIZED RATIO; MESENTERIC VEIN; MIDDLE AGED; PORTAL VEIN; RECURRENT DISEASE; RETROSPECTIVE STUDY; SPLENIC VEIN; STROKE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOPHILIA; TREATMENT FAILURE; VENOUS THROMBOSIS;

ADULT; ANTICOAGULANTS; ANTIPHOSPHOLIPID SYNDROME; BENZIMIDAZOLES; BETA-ALANINE; CEREBRAL INFARCTION; DRUG SUBSTITUTION; FEMALE; HUMANS; INTERNATIONAL NORMALIZED RATIO; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MESENTERIC VEINS; MIDDLE AGED; MORPHOLINES; PORTAL VEIN; RECURRENCE; RETROSPECTIVE STUDIES; SPLENIC VEIN; STROKE; THIOPHENES; THROMBOEMBOLISM; THROMBOPHILIA; TREATMENT FAILURE; VENOUS THROMBOSIS; WARFARIN;

EID: 84908550562     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH14-03-0272     Document Type: Article

References (17)

1. Miyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306.
2. Meroni PL, Borghi MO, Raschi E, et al. Pathogenesis of antiphospholipid syndrome: understanding the antibodies. Nat Rev Rheumatol 2011; 7: 330-339.
3. Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011; 20: 206-218.
4. Lim W, Crowther MA, Eikelboom JW. Management of antiphospholipid antibody syndrome: a systematic review. J Am Med Assoc 2006; 295: 1050-1057.
5. Ruiz-Irastorza G, Hunt BJ, Khamashta MA. A systematic review of secondary thromboprophylaxis in patients with antiphospholipid antibodies. Arthritis Rheum 2007; 57: 1487-1495.
6. Garcia D, Akl EA, Carr R, et al. Antiphospholipid antibodies and the risk of recurrence after a first episode of venous thromboembolism: a systematic review. Blood 2013; 122: 817-824.
7. Ketha SS, Pruthi RK, McBane RD, et al. Lupus anticoagulant, warfarin, and alternative laboratory monitoring of anticoagulation. J Thromb Thrombolysis 2013; Epub ahead of print.
8. European Medicines Agency-Xarelto (Internet). (cited 2014 Mar 5). Available from: http://www. ema. europa. eu/ema/index. jsp?curl=pages/medicines/human/medicines/000944/human_med_001155. jsp.
9. Press Announcements > FDA expands use of Xarelto to treat, reduce recurrence of blood clots (Internet). (cited 2014 Mar 5). Available from: http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm326654. htm.
10. European Medicines Agency-Pradaxa (Internet). (cited 2014 Mar 5). Available from: http://www. ema. europa. eu/ema/index. jsp?curl=pages/medicines/human/medicines/000829/human_med_000981. jsp.
11. Press Announcements > FDA approves Pradaxa to prevent stroke in people with atrial fibrillation (Internet). (cited 2014 Mar 5). Available from: http://www. fda. gov/NewsEvents/Newsroom/PressAnnouncements/ucm230241. htm.
12. Tahir F, Riaz H, Riaz T, et al. The new oral anti-coagulants and the phase 3 clinical trials-a systematic review of the literature. Thromb J 2013; 11: 18.
13. Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 2013; 15: 331.
14. ISRCTN68222801-Rivaroxaban in Antiphospholipid Syndrome (RAPS) (Internet). (cited 2014 Mar 5). Available from: http://www. controlled-trials. com/ISRCTN68222801.
15. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891.
16. Crowther MA, Ginsberg JS, Julian J, et al. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome. N Engl J Med 2003; 349: 1133-1138.
17. Finazzi G, Marchioli R, Brancaccio V, et al. A randomized clinical trial of highintensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS). J Thromb Haemost 2005; 3: 848-853.